#OVCEnterprises# updates: DR Laser's global HQ phase III has started construction; Topgene Biotech's Biolake HQ is now open; EasyDiagnosis has acquired Bcare, expanding into emergency care; and HG Laser's hydrogen energy production line has gone global.

MssCorp (TWE: 6830) Serenity High Conviction Bet（analysis fully grounded in TSMC’s latest public expansion plans and 2026 industry data）： – this is the functional monopoly in CPO/SiPh inspection (90%+ share targeted, pricing power is real). Long list of customers ($TSM, $NVDA, $AAPL, $AMAT , $LRCX, $ASML , $INTC ) all need to go through them for yields. NVIDIA dedicated AI Chip Zone in US facility = strategic lock-in. -GS CPO TAM still the anchor: $91B by 2028. -TSMC CoWoS doubling to 130k-140k wafers per month by end-2026 via AP7 Chiayi (world’s largest advanced packaging hub, CoPoS pilot 2026/volume ramp 2027-28) + AP8 Tainan (P1/P2) + AP5/AP6 upgrades. We are still in the frontrunning window. Pure TSMC fab expansion model only — no NVIDIA exclusive assumed. Factory-by-factory HG demand: HG is specialized QA/FA tool (not standard per-line gear). Base Assumption~60 units per major packaging “module group” (20 front / 20 mid / 20 back). Using latest TSMC 2026 data: AP6 (Longtan/Taichung): Operating + upgrade → ~30 units / MssCorp 25-30 units AP7 Chiayi: World’s largest, CoPoS pilot → ~45-120 units / MssCorp 40-100 units AP8 Tainan (P1-P2): Construction/ramp → ~120 units/ MssCorp 100-110 units AP8 later phases + AP9: 2028+ planning → ~240-260 units / MssCorp 200-220 units TSMC only total: ~435-530 units / MssCorp 365-460 units Updated HG model (reflecting monopoly + pricing power): Industry total demand 130-200 units 26-30. With 90%+ monopoly → MssCorp ships 120-180 units (spares + repeat buys). ASP NT$60M (pricing power) + GM 60-75%. HG contribution build (NT$ bn, cumulative 2026-2030): Equipment sales + Recurring services/consumables (25–45% of equipment value over 5 years) + IP licensing (20–35% of equipment rev, 80-90% margin). Total HG contribution NT$9.5bn–NT$13bn. Core MA/FA business growing 20-30% CAGR from NT$22B 2025 base on top. Revenue path (NT$ bn): 2026: 30–38 2027: 45–62 2028: 65–88 2029-30+: 180–240/yr (normalized) Mix shifts hard to high-margin equipment + recurring + IP as CPO goes volume Share count 51.78M. With the structural monopoly in a critical yield choke-point + TSMC/NVIDIA tailwinds, long-term normalized forward EPS can realistically reach NT$180–240 (US$5.6–7.5). 40–60x forward P/E (standard for AI/SiPh leaders with real moats) → target NT$5,000+. Current MC ~$1.2–1.4B.